Form 4: Recursion Pharmaceuticals Director Blake Borgeson Sells Shares Under 10b5-1 Plan

Director Blake Borgeson of Recursion Pharmaceuticals sold 20,054 shares of Class A Common Stock at an average price of $10.1194 under a pre-arranged 10b5-1 trading plan.

Summary

• On May 14, 2024, Blake Borgeson, a director of Recursion Pharmaceuticals, sold 20,054 shares of Class A Common Stock.
• The sale was executed at a weighted average price of $10.1194, with individual trades ranging from $9.74 to $10.50.
• The transaction was conducted under a Rule 10b5-1 trading plan adopted on August 18, 2023.
• Following the transaction, Borgeson still beneficially owns 7,198,360 shares of Recursion Pharmaceuticals.
• The reporting person has undertaken to provide full information regarding the number of shares sold at each separate sale price upon request.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating a routine transaction. The use of a 10b5-1 plan suggests no negative implications.

Industry Context

Sales by company directors are a normal part of corporate governance. The use of a 10b5-1 trading plan suggests the director planned the transaction in advance to avoid accusations of insider trading.

Stakeholder Impact

• The sale of shares by a director could have a minor negative impact on shareholder sentiment, but the existence of a 10b5-1 plan mitigates this concern.

Key Dates